Melanoma is a highly aggressive form of skin cancer. It affects melanocytes, the cells responsible for the synthesis of melanin, which gives the skin its colour. There are 3 stages of tumour progression: radial growth, in which the cells proliferate in a disordered manner in the epidermis, the vertical growth phase, which involves invasion of the dermis, and finally the metastatic phase, corresponding to the dissemination of the cancer cells in the peripheral tissues.
Although encouraging results have been obtained for treating the metastatic phase (using targeted therapies or immunotherapies), most patients will need additional treatments to prevent the tumour from coming back, and to prevent more metastases from developing. The identification of new drug candidates is therefore an unavoidable element for the establishment of effective biotherapies against this cancer, the incidence of which is doubling every ten years.
In this context, researchers from Nice discovered a new family of drugs, the Thiazole Benzensulfonamides (TZB), which have useful anticancer properties. “Initially this family of drugs was identified in type 2 diabetes, as it increased the sensitivity of cells to insulin. If we wanted to use it against cancer, we had to be able to eliminate this proinsulin activity,” explains Stéphane Rocchi. “Thus we started to modify its structure.”
After many attempts, the initial TZD structure was extensively modified thanks to a fruitful collaboration with Dr Benhida’s team from the Nice Institute of Chemistry, to obtain a formulation in which the “lead compound” was called HA15.
In the mouse, this drug is highly effective in reducing the tumour volume without obvious toxicity in the rodent.
In humans, in collaboration with the Dermatology Department in Nice University Hospital, the researchers showed that the drugs were active on melanoma cells from biopsies taken from patients who were sensitive or resistant to targeted therapies.
Finally, HA15 is also effective on cell lines from other tumours such as cancer of the breast, colon, prostate, pancreas, and even gliomas and chronic myeloid leukaemias.
“The ultimate goal of this project is to use these new drugs to treat melanoma, and more generally in other types of cancers,” concludes Stéphane Rocchi, who hopes to start a phase I clinical trial soon.
This work has been the subject of two 2 patent applications filed by INSERM Transfert and a presentation to the MATWIN programme for technology transfer, and has received funding for maturation from Canceropole PACA and INSERM Transfert (Grand COPOC).
Une molécule issue d’un champignon comestible pourrait ouvrir des perspectives thérapeutiques pour des patients atteints de mucoviscidose, la maladie génétique rare la plus fréquente. Une équipe de recherche dirigée....